On Target Laboratories Founder Philip Low Receives Legacy Award from the American Lung Association
WEST LAFAYETTE, Ind., April 1, 2024 /PRNewswire/ -- Dr. Philip S. Low, Founder and Chief Science Officer of On Target Laboratories, Inc., will receive the Indiana American Lung Association's (ALA) Legacy Award for his lifetime and innovative work on targeted molecules. The annual Indiana ALA Legacy Award is given to individuals or organizations whose accomplishments are contributing to ending lung cancer and will be presented to Dr. Low at the ALA's "Evening of Promise Gala" in Indianapolis on Saturday, April 13.
- Founder and Purdue University researcher Philip Low to be recognized for his invention of CYTALUX, a fluorescent targeted molecule that illuminates lung cancer cells during surgery
WEST LAFAYETTE, Ind., April 1, 2024 /PRNewswire/ -- Dr. Philip S. Low, Founder and Chief Science Officer of On Target Laboratories, Inc., will receive the Indiana American Lung Association's (ALA) Legacy Award for his lifetime and innovative work on targeted molecules. - Dr. Low invented CYTALUX as part of his founding work with On Target Laboratories, a privately held biotechnology company whose mission is to illuminate cancer so it can be removed completely.
- "We are proud that our Founder and Chief Science Officer, Dr. Low, is being celebrated for his dedication and innovative work to illuminate cancer during surgery," said Ben Lundgren, Chief Executive Officer of On Target Laboratories.
- "I am honored to be receiving this year's Legacy Award from the Indiana American Lung Association," said Dr. Low.